Even more crucial, though, will be to establish valid systems to study the physiological role of Siglec-16 and its engagement as potentially activating counterpart of Siglec-11 in responses to polySia released under neuroinflammatory conditions, or presented, e.g., on the surface of tumor cells1. The gene discussed is SIGLEC11; the disease is neoplasm.